Table 5 Colonization in surveillance samples by colistin- and tobramycin-resistant pathogens
Variables | SDD period (between October 2011 and September 2015) | ||||
|---|---|---|---|---|---|
Total | 1st year | 2nd year | 3rd year | 4th year | |
(n = 285) | (n = 59) | (n = 56) | (n = 69) | (n = 101) | |
Male sex, % | 66.7 | 67.8 | 71.4 | 60.9 | 67.2 |
Age, years, mean ± SD | 60.7 ± 15.0 | 56.2 ± 14.4 | 61.0 ± 16.0 | 61.3 ± 12.4 | 62.4 ± 16.1 |
Total patients | 3948 | 1067 | 1069 | 851 | 961 |
Patients with SDD | 1998 | 522 | 381 | 430 | 665 |
Colistin | |||||
Resistance at ICU admission | 113 (39.6) | 5 (8.5) | 17 (30.4) | 30 (43.5) | 61 (60.4) |
Development of resistance | 30 (10.5) | 3 (5.1) | 8 (14.3) | 7 (10.1) | 12 (11.9) |
Observed (at ICU admission) | |||||
Rate/100 patients | 2.86 | 0.47 | 1.59 | 3.53 | 6.35 |
Rate/100 patients SDD | 5.66 | 0.96 | 4.46 | 6.98 | 9.17 |
Estimated (acquired in ICU) | |||||
Rate/100 patients | 0.76 | 0.28 | 0.75 | 0.82 | 1.25 |
Rate/100 patients SDD | 1.5 | 0.57 | 2.1 | 1.63 | 1.8 |
Tobramycin | |||||
Resistance at ICU admission | 151 (52.9) | 17 (6.0) | 32 (11.2) | 34 (11.9) | 68 (23.9) |
Development of resistance | 30 (10.5) | 1 (0.4) | 3 (1.1) | 15 (5.3) | 11 (3.9) |
Observed (at ICU admission) | |||||
Rate/100 patients | 3.82 | 1.59 | 2.99 | 3.99 | 7.08 |
Rate/100 patients SDD | 7.56 | 3.26 | 8.4 | 7.91 | 10.23 |
Estimated (acquired in ICU) | – | ||||
Rate/100 patients | 0.76 | 0.09 | 0.28 | 1.76 | 1.14 |
Rate/100 patients SDD | 1.5 | 0.19 | 0.79 | 3.49 | 1.65 |